A/Prof. Stacker is head of the Tumor Angiogenesis Program at the Peter MacCallum Cancer Centre in Melbourne. Previously he worked for two decades at the Melbourne Branch of the Ludwig Institute for Cancer Research where he was Associate Director and Joint-Head of the Angiogenesis Laboratory. He received his Ph.D. from the University of Melbourne on work characterising mucins associated with breast cancer and subsequently developing serum markers for the diagnosis of breast cancer. He undertook post-doctoral training with Dr. Timothy Springer at the Dana-Farber Cancer Institute and Centre for Blood Research, Harvard Medical School, Boston from 1988-1991. He has published more than 100 articles and 15 patents in the area of vascular biology, cell adhesion and tumour detection. He is recognised internationally for his work on identifying new members of the VEGF family. He demonstrated that the tumour lymphangiogenic properties of VEGF-D result in lymphatic metastasis and their inhibition blocks tumour metastasis. His work has contributed to the formation of three companies, Integrated Medical Technologies, Lymphatix Ltd and Vegenics Ltd. which focused on developing therapeutics and biomarkers for vascular disease and cancer. A/Prof. Stacker was the inaugural holder of the Pfizer Australia Senior Research Fellowship and is currently supported by an NHMRC Research Fellowship and NHMRC Program Grant. His current work tries to understand the unique signalling pathways in lymphatic endothelial cells with the aim of identifying new targets for therapeutics in vascular disease and cancer.